New Lung Cancer Therapy May Target Previously Untreatable Tumors (Memorial Sloan Kettering Cancer Center)
Although some lung cancer patients have benefited from developments in precision therapy, those with mutations in a gene called KRAS have not. Now Memorial Sloan Kettering Cancer Center researchers are developing uses for a compound that targets a common KRAS mutation in lung cancer.
Memorial Sloan Kettering Cancer Center is one of the 26 NCCN Member Institutions.
...
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news